HomeComparePLXP vs JNJ

PLXP vs JNJ: Dividend Comparison 2026

PLXP yields 2298.85% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLXP wins by $36577739038.82M in total portfolio value
10 years
PLXP
PLXP
● Live price
2298.85%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36577739038.85M
Annual income
$33,694,466,973,692,370.00
Full PLXP calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — PLXP vs JNJ

📍 PLXP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPLXPJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PLXP + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PLXP pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PLXP
Annual income on $10K today (after 15% tax)
$195,402.30/yr
After 10yr DRIP, annual income (after tax)
$28,640,296,927,638,510.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, PLXP beats the other by $28,640,296,927,634,530.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PLXP + JNJ for your $10,000?

PLXP: 50%JNJ: 50%
100% JNJ50/50100% PLXP
Portfolio after 10yr
$18288869519.44M
Annual income
$16,847,233,486,848,528.00/yr
Blended yield
92.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PLXP
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Altman Z
-10.3
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PLXP buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPLXPJNJ
Forward yield2298.85%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$36577739038.85M$30.3K
Annual income after 10y$33,694,466,973,692,370.00$4,689.40
Total dividends collected$36375156338.99M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: PLXP vs JNJ ($10,000, DRIP)

YearPLXP PortfolioPLXP Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$240,585$229,885.06$10,592$272.30+$230.0KPLXP
2$5,426,296$5,168,870.07$11,289$357.73+$5.42MPLXP
3$114,761,014$108,954,877.01$12,123$472.89+$114.75MPLXP
4$2,276,338,467$2,153,544,182.26$13,141$629.86+$2276.33MPLXP
5$42,357,698,654$39,922,016,494.37$14,408$846.81+$42357.68MPLXP
6$739,586,041,815$694,263,304,255.43$16,021$1,151.60+$739586.03MPLXP
7$12,120,492,876,395$11,329,135,811,652.31$18,122$1,588.22+$12120492.86MPLXP
8$186,486,946,005,072$173,518,018,627,329.40$20,930$2,228.20+$186486945.98MPLXP
9$2,694,646,789,868,656$2,495,105,757,643,229.00$24,792$3,191.91+$2694646789.84MPLXP
10$36,577,739,038,851,830$33,694,466,973,692,370.00$30,274$4,689.40+$36577739038.82MPLXP

PLXP vs JNJ: Complete Analysis 2026

PLXPStock

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

Full PLXP Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this PLXP vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PLXP vs SCHDPLXP vs JEPIPLXP vs OPLXP vs KOPLXP vs MAINPLXP vs ABBVPLXP vs MRKPLXP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.